InMode (NASDAQ:INMD - Get Free Report) updated its FY25 earnings guidance on Tuesday. The company provided EPS guidance of $1.95-$1.99 for the period, compared to the consensus EPS estimate of $1.98. The company issued revenue guidance of $395-$405 million, compared to the consensus revenue estimate of $413.47 million.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. Barclays lifted their price target on shares of InMode from $26.00 to $29.00 and gave the stock an "overweight" rating in a report on Wednesday. BTIG Research initiated coverage on InMode in a report on Thursday, October 17th. They set a "buy" rating and a $25.00 target price on the stock. Finally, Needham & Company LLC reissued a "hold" rating on shares of InMode in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, InMode currently has an average rating of "Hold" and a consensus target price of $23.00.
Check Out Our Latest Research Report on InMode
InMode Trading Down 1.2 %
INMD stock traded down $0.21 during midday trading on Friday, hitting $18.04. The stock had a trading volume of 1,220,008 shares, compared to its average volume of 866,573. The business has a fifty day moving average price of $17.36 and a two-hundred day moving average price of $17.21. InMode has a 1-year low of $14.87 and a 1-year high of $26.80. The firm has a market cap of $1.25 billion, a P/E ratio of 7.68 and a beta of 2.13.
InMode Company Profile
(
Get Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
See Also
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
